drugset / Trial / NCT02797171

Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults

NCT02797171

RandomizedParallel-groupOpen-labelPrevention

Summary

This study will evaluate the safety, pharmacokinetics, and antiviral activity of VRC-HIVMAB060-00-AB (VRC01) and VRC-HIVMAB080-00-AB (VRC01LS) in the serum and mucosa of healthy, HIV-uninfected adults.

Timeline

Start
2017-03-01
Primary completion
2019-06-05
Completion
2019-06-05

Drugs

EvaluationDrugModalityDoseRoute
Subject VRC01 Monoclonal antibody 10 mg/kg Intravenous
Subject VRC01 Monoclonal antibody 30 mg/kg Intravenous
Subject VRC01LS Monoclonal antibody 30 mg/kg Intravenous